If you're interested in capitalizing on the rapidly growing weight management market, you might naturally consider investing in Eli Lilly and Novo Nordisk. That's not a bad strategy since these two ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

You have been exercising, eating home-cooked meals, and have managed to cut out fried food and desserts from your diet for ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity ...

A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or ...

Cipla Limited is planning to enter the weight management segment in India, announced the company’s MD and global CEO Umang ...

Mumbai: Mumbai-based pharma giant Cipla is gearing up to make an entry into India's rapidly growing weight management market, ...

The pharma major is also strengthening its presence in the central nervous system (CNS) therapeutic area, Vohra stated ...

Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and ...

Pharmaceutical giant Cipla plans to enter India's weight management sector, while also bolstering its central nervous system ...